Gunderson Dettmer represented client Tarsus Pharmaceuticals, a biopharmaceutical company, in its upsized underwritten public offering of 5,600,000 shares of common stock at a public offering price of $13.50 per share which represents $75.6 million of common stock. The company focuses on advancing its pipeline to address several diseases with high unmet needs across a range of therapeutic categories, including eye care. 

The Gunderson deal team was co-led by Ryan Gunderson and Ilan Lovinsky and included Leanne Gould and Bettina Tiangco.